Key Market Segments:
By Product
-
-
Test Kit and Reagents
-
-
-
Instruments
-
Others
-
By End-use
-
-
Hospitals and clinic
-
-
-
Diagnostic Labs
-
Others
-
By Test
-
-
Traditional Influenza Diagnostic Tests
-
Rapid Influenza Diagnostic Tests (RIDTs)
-
Direct Fluorescent Antibody (DFA) Tests
-
Viral Culture
-
Serological Assays
-
-
-
-
Molecular Influenza Diagnostic Tests
-
Reverse Transcription Polymerase Chain Reaction (RT-PCR)
-
Isothermal Nucleic Acid Amplification Tests (INAAT)
-
Loop-Mediated Isothermal-based Amplification Assays
-
Transcription Mediated Isothermal-based Amplification Assays
-
-
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
-
US
-
Canada
-
Mexico
Europe
-
Eastern Europe
-
Poland
-
Romania
-
Hungary
-
Turkey
-
Rest of Eastern Europe
-
-
Western Europe
-
Germany
-
France
-
UK
-
Italy
-
Spain
-
Netherlands
-
Switzerland
-
Austria
-
Rest of Western Europe
-
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Vietnam
-
Singapore
-
Australia
-
Rest of Asia Pacific
Middle East & Africa
Middle East
-
UAE
-
Egypt
-
Saudi Arabia
-
Qatar
-
Rest of the Middle East
Africa
-
Nigeria
-
South Africa
-
Rest of Africa
Latin America
-
Brazil
-
Argentina
-
Colombia
-
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Product Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Product Matrix which gives a detailed comparison of the product portfolio of each company
-
Geographic Analysis
-
Additional countries in any of the regions
-
Company Information
-
Detailed analysis and profiling of additional market players (Up to five)
Frequently Asked Questions
Ans: Variability in test accuracy and limited awareness and training among healthcare providers are significant challenges
Ans: Molecular influenza diagnostic tests are expected to grow at the highest CAGR of about 6.31% from 2024 to 2032.
Ans: The ongoing rate of infectious diseases and increasing demand for effective diagnostic solutions are key drivers.
Ans: Influenza Diagnostics Market was valued at USD1.49 billion in 2023 and is expected to reach USD 2.45 billion by 2032, growing at a CAGR of 5.69 % from 2024-2032.